Hmdb loader
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2021-09-11 17:09:19 UTC
Update Date2022-11-23 21:39:02 UTC
HMDB IDHMDB0256624
Secondary Accession NumbersNone
Metabolite Identification
Common Name2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide
DescriptionN~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE, also known as 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide or 2-(dimethylaminoacetylamino)-5,6-dihydrophenanthridine-6-one, belongs to the class of organic compounds known as phenanthridines and derivatives. These are polycyclic compounds containing a phenanthridine moiety, which is a tricyclic system with two benzene rings joined by a pyridine forming a non-linear skeleton. Hydrogenated derivatives are also included. Based on a literature review a significant number of articles have been published on N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE. This compound has been identified in human blood as reported by (PMID: 31557052 ). 2-(dimethylamino)-n-(6-oxo-5h-phenanthridin-2-yl)acetamide is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.
Structure
Thumb
Synonyms
ValueSource
2-(Dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamideChEBI
2-(Dimethylaminoacetylamino)-5,6-dihydrophenanthridine-6-oneChEBI
N-(5,6-Dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)acetamideChEBI
N-(5,6-Dihydro-6-oxophenanthridine-2-yl)-2-(dimethylamino)acetamideChEBI
N(2),N(2)-Dimethyl-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)glycinamideChEBI
PJ 34ChEBI
PJ-34ChEBI
N-(oxo-5,6-Dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochlorideMeSH
2-(Dimethylamino)-N-(6-hydroxyphenanthridin-2-yl)ethanimidateGenerator
Chemical FormulaC17H17N3O2
Average Molecular Weight295.3358
Monoisotopic Molecular Weight295.132076803
IUPAC Name2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide
Traditional Name2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide
CAS Registry NumberNot Available
SMILES
CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1
InChI Identifier
InChI=1S/C17H17N3O2/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22)
InChI KeyUYJZZVDLGDDTCL-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as phenanthridines and derivatives. These are polycyclic compounds containing a phenanthridine moiety, which is a tricyclic system with two benzene rings joined by a pyridine forming a non-linear skeleton. Hydrogenated derivatives are also included.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassBenzoquinolines
Direct ParentPhenanthridines and derivatives
Alternative Parents
Substituents
  • Phenanthridine
  • Alpha-amino acid amide
  • Dihydroquinolone
  • Isoquinolone
  • Alpha-amino acid or derivatives
  • Dihydroquinoline
  • Isoquinoline
  • N-arylamide
  • Pyridinone
  • Pyridine
  • Benzenoid
  • Heteroaromatic compound
  • Secondary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Amino acid or derivatives
  • Carboxamide group
  • Lactam
  • Azacycle
  • Carboxylic acid derivative
  • Organic oxygen compound
  • Organic oxide
  • Organopnictogen compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Carbonyl group
  • Organooxygen compound
  • Amine
  • Organic nitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP1.88ALOGPS
logP1.87ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)11.07ChemAxon
pKa (Strongest Basic)7.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.44 ŲChemAxon
Rotatable Bond Count3ChemAxon
Refractivity88.96 m³·mol⁻¹ChemAxon
Polarizability32.1 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M-2H]-203.03730932474
DeepCCS[M+Na]+178.29730932474
AllCCS[M+H]+168.532859911
AllCCS[M+H-H2O]+165.032859911
AllCCS[M+NH4]+171.732859911
AllCCS[M+Na]+172.632859911
AllCCS[M-H]-174.632859911
AllCCS[M+Na-2H]-174.232859911
AllCCS[M+HCOO]-173.932859911

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. 3.56 minutes32390414
Predicted by Siyang on May 30, 20229.7438 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20223.22 minutes32390414
Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid847.2 seconds40023050
Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid235.0 seconds40023050
Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid110.0 seconds40023050
Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid177.7 seconds40023050
RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid56.1 seconds40023050
Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid263.7 seconds40023050
BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid331.6 seconds40023050
HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate)534.1 seconds40023050
UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid565.2 seconds40023050
BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid65.6 seconds40023050
UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid857.6 seconds40023050
SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid205.1 seconds40023050
RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid254.4 seconds40023050
MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate466.6 seconds40023050
KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA571.9 seconds40023050
Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water54.8 seconds40023050

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamideCN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C13739.6Standard polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamideCN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C12850.5Standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamideCN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C13217.5Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #1CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C2750.3Semi standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #1CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C2875.7Standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #1CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C3468.6Standard polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #2CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C2964.6Semi standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #2CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C2898.5Standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TMS,isomer #2CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C3586.8Standard polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TMS,isomer #1CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C)[Si](C)(C)C2750.0Semi standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TMS,isomer #1CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C)[Si](C)(C)C2880.5Standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TMS,isomer #1CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C)[Si](C)(C)C3147.6Standard polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #1CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C(C)(C)C3011.7Semi standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #1CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C(C)(C)C3050.6Standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #1CN(C)CC(=O)N(C1=CC=C2[NH]C(=O)C3=CC=CC=C3C2=C1)[Si](C)(C)C(C)(C)C3516.8Standard polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #2CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C3168.0Semi standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #2CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C3059.1Standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,1TBDMS,isomer #2CN(C)CC(=O)NC1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C3607.4Standard polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TBDMS,isomer #1CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3217.7Semi standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TBDMS,isomer #1CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3235.9Standard non polar33892256
N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide,2TBDMS,isomer #1CN(C)CC(=O)N(C1=CC=C2C(=C1)C1=CC=CC=C1C(=O)N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C3314.5Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide GC-MS (Non-derivatized) - 70eV, Positivesplash10-0a4i-9480000000-81f18565b12a4c82c3bf2017-08-28Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide 10V, Positive-QTOFsplash10-0002-1090000000-f38097341583d305e6342017-07-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide 20V, Positive-QTOFsplash10-0a4i-3090000000-eef729346319d8c590e52017-07-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide 40V, Positive-QTOFsplash10-08gi-9450000000-24e86545c42e9bcd4b4e2017-07-25Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide 10V, Negative-QTOFsplash10-0006-0090000000-188e33603d888c8255a32017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide 20V, Negative-QTOFsplash10-052f-1090000000-20484bf7794d315dda672017-07-26Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide 40V, Negative-QTOFsplash10-0a4i-3390000000-559cfdd7a2be23d1d3e72017-07-26Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB08348
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID4692
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI ID167900
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]